编号：2018-001 证券代码：002919 证券简称：名臣健康 投资者关系活动记录表 | --- | --- | |-----------------------|--------------------------------------------------------------| | | | | | 特定对象调研 □分析师会议 | | | □ 媒体采访 □业绩说明会 | | 投资者关系活动 类别 | □ 新闻发布会 □路演活动 | | | □ 现场参观 | | | □ 其他（请文字说明其他活动内容） | | 参与单位名称及 | 中金公司 樊俊豪 | | 人员姓名 | | | 时间 | 2018 年 2 月 6 日 14:00-17:00 | | 地点 | 名臣健康用品股份有限公司 3 楼会议室 | | 上市公司接待人 员姓名 | 名臣健康用品股份有限公司董事长陈勤发、董秘陈东松 | | 投资者关系活动 | 一、公司董事长陈勤发先生向调研人员介绍调研相关注意事项、签署 | | 主要内容介绍 | 承诺 | | | 二、问答环节 | | | 1 、品牌是一个企业长期的积淀，在日化行业中，比如公司的 | ...

证券代码：002919 证券简称：名臣健康 编号： 2018-003 投资者关系活动记录表 | --- | --- | --- | |---------------------|--------------------------------------------|------------------------------------------------------| | | | | | | □ 特定对象调研 □分析师会议 | | | | □媒体采访 □业绩说明会 | | | 投资者关系活动 类别 | □ 新闻发布会 □路演活动 | | | | □现场参观 | | | | 其他（电话会谈） | | | 参与单位名称及 | 中信里昂证券 张嘉瑜 | | | 人员姓名 | | | | 时间 | 2018 年 6 月 28 日 14:00-14:35 | | | 方式 | 电话会谈 | | | 上市公司接待人 | 名臣健康用品股份有限公司董秘陈东松 | | | 员姓名 | | | | 投资者关系活动 | | 一、公司人员向调研人员介绍调研相关注意事项、签署承诺 | | 主要内容介绍 | 二、问答环节 | | ...

Group 1: Company Operations and Management - The daily operations of the company are managed by the board of directors, with Chairman Chen Qinfang also serving as the General Manager, making key decisions for daily business management [3] - The company is considering employee stock ownership or equity incentive plans in the future [3] - The decline in Q1 performance is attributed to the impact of the traditional Spring Festival, which affected order fulfillment due to extended holidays and adverse weather conditions [3] Group 2: Brand and Marketing Strategy - The selection criteria for brand ambassadors include a good overall image and reputation, with a focus on appealing to younger consumers [4] - The brand ambassador for "Ti Hua Zhi Xiu" is Wang Likun, known as the "Bare-faced Goddess," while "Mei Wang" is represented by the "Jiu Yue Qi Ji" group [4] - The company has a significant presence in supermarkets, with a notable market share among domestic brands, particularly for the "Ti Hua Zhi Xiu" brand [4] Group 3: Sales Channels and E-commerce - The company primarily opens stores through distributors, with a significant expansion in physical store presence [5] - Currently, the company does not operate its own online stores but relies on authorized distributors on platforms like JD, Taobao, Tmall, and Pinduoduo [5] - The company plans to launch new brands, including "Chu Cui," which targets sensitive skin care and was showcased at the 2018 Shanghai Beauty Expo [5] Group 4: Future Development and Product Innovation - The company aims to develop higher-end products in response to the evolving consumer market, particularly targeting younger demographics [6] - The company is focused on enhancing product quality while seeking innovative breakthroughs in product development [7] - The name "Ming Chen Health" reflects the company's commitment to personal health care and beauty, with plans to explore the broader "big health" sector [7][8]

证券代码：002919 证券简称：名臣健康 投资者关系活动记录表 编号：2021-001 | --- | --- | --- | |----------------|----------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------| | | | | | | □特定对象调研 | □分析师会议 | | | □媒体采访 □业绩说明会 | | | 投资者关系活动 | □新闻发布会 | □路演活动 | | 类别 | □现场参观 | | | | 其他（电话会议） | | | 参与单位名称 | | 信诚基金、富安达基金、博时基金、东吴基金、万家基金、新 时代证券、上海证券、华西证券、东方证券、招银理财、盈科 资本、泓信投资、乾信投资、麦星投资、道谊资产、玖龙资产、 | | | | 创迈投资、百年保险 ...

证券代码：002919 证券简称：名臣健康 投资者关系活动记录表 编号：2022-001 | --- | --- | --- | --- | |--------------------------------------|-----------------------------|---------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------| | | | | | | | □特定对象调研 | □分析师会议 | | | | | □媒体采访 □业绩说明会 | | | 投资者关系活动 | □新闻发布会 | □路演活动 | | | 类别 ...

Financial Performance - The company's revenue for Q3 2022 was ¥218,438,464.02, representing a 27.29% increase compared to the same period last year[5] - The net profit attributable to shareholders was -¥45,526,989.51, a decrease of 305.80% year-on-year[5] - The net cash flow from operating activities was -¥91,884,294.74, a significant decline of 2,529.31% compared to the previous year[5] - The company's basic earnings per share were -¥0.27, down 307.69% year-on-year[5] - The company reported a net operating loss of RMB 29,404,454.99, a significant decline from a profit of RMB 120,971,502.78 in the previous period[26] - The net profit for the third quarter of 2022 was -18,380,380.51 CNY, compared to a net profit of 121,021,881.50 CNY in the same period last year, indicating a significant decline[27] - The total revenue from operating activities was 556,680,888.09 CNY, down from 577,286,645.38 CNY year-over-year, reflecting a decrease of approximately 3.5%[28] - The company experienced a total comprehensive loss of -18,380,380.51 CNY for the quarter, aligning with the net loss reported[27] Assets and Liabilities - Total assets at the end of the reporting period were ¥978,654,484.61, an increase of 0.86% from the end of the previous year[5] - Total liabilities increased to RMB 283,116,750.51 from RMB 212,535,291.07, indicating a significant rise in financial obligations[24] - The total equity attributable to shareholders decreased to RMB 695,537,734.10 from RMB 757,810,648.61, reflecting a decline in shareholder value[24] Operating Costs and Expenses - The company's operating costs increased by 44.28% to ¥391,488,946.25 due to significant promotional investments in overseas markets[11] - Operating costs surged to RMB 592,534,091.04, compared to RMB 451,708,983.89 in the prior period, reflecting increased operational expenses[26] - Research and development expenses rose to RMB 77,079,189.10, up from RMB 69,316,626.75, highlighting a focus on innovation[26] Shareholder Information - Total number of common shareholders at the end of the reporting period is 4,986[14] - The largest shareholder, Chen Qinfang, holds 37.00% of shares, totaling 63,270,900 shares[14] - The company plans to repurchase shares with a total fund of no less than RMB 50 million and no more than RMB 100 million, at a price not exceeding RMB 35.00 per share[16] - The repurchase price has been adjusted to not exceed RMB 24.79 per share, with an estimated repurchase quantity of 201,694.2 shares at the lower limit and 403,388.4 shares at the upper limit[18] - As of September 30, 2022, the company has repurchased a total of 390,000 shares, accounting for 0.11% of the total share capital, with a total payment of RMB 7,250,795.4[19] - The company distributed cash dividends of RMB 3 per 10 shares, totaling RMB 36,640,723.5, and increased total share capital by 48,854,298 shares through capital reserve conversion[19] Government Support and Investments - The company received government subsidies amounting to ¥6,631,472.74, a 611.12% increase compared to the previous year[11] - The company plans to continue expanding its market presence and investing in new game development despite current challenges[11] - The company transferred assets related to its daily chemical business to its wholly-owned subsidiary, with a book value of RMB 181,202,454.10[20] - The company plans to acquire 100% equity of Kashgar Aoshut Network Technology Co., Ltd. for RMB 21,900 million, with a 30% advance payment already made[21] - The company is actively progressing with the acquisition project, with further details disclosed in public announcements[21] Cash Flow and Liquidity - The company's cash and cash equivalents decreased to RMB 121,681,883.77 from RMB 250,898,429.01, indicating liquidity challenges[23] - The cash inflow from investment activities was 227,103,942.61 CNY, down from 374,835,397.52 CNY year-over-year, indicating a decline in cash generated from investments[28] - The total cash outflow from investing activities was 216,512,219.29 CNY, compared to 320,561,837.02 CNY in the previous year, indicating a reduction in investment expenditures[28] - The cash flow from financing activities resulted in a net outflow of -49,724,015.09 CNY, compared to -73,667,624.02 CNY in the same period last year, showing an improvement in financing cash flow[29] - The cash and cash equivalents at the end of the period were 121,681,883.77 CNY, down from 175,823,317.82 CNY at the end of the previous year, representing a decrease of about 30.8%[29] Market and Product Development - The company did not report any new product launches or significant market expansion strategies during this quarter[30]

证券代码：002919 证券简称：名臣健康 公告编号：2022-043 名臣健康用品股份有限公司 关于参加广东辖区上市公司 2022 年投资者网上 集体接待日活动的公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚 假记载、误导性陈述或重大遗漏。 为进一步加强与投资者的互动交流，名臣健康用品股份有限公司（以下简称 "公司"）将参加由广东证监局、广东上市公司协会联合举办的"2022 年广东 辖区上市公司投资者网上集体接待日活动"，现将相关事项公告如下： 本次投资者网上集体接待日活动将通过深圳市全景网络有限公司提供的网 上平台举行，投资者可以登录"全景·路演天下"网站（http://rs.p5w.net） 参与公司本次投资者网上集体接待日活动。网上互动交流时间为 2022 年 9 月 22 日（星期四）15:50-16:50。 届时公司部分高管将在线就公司业绩、公司治理、发展战略、经营状况和可 持续发展等投资者关心的问题，与投资者进行沟通与交流，欢迎广大投资者踊跃 参与。 特此公告。 名臣健康用品股份有限公司 董事会 二〇二二年九月二十日 ...

Financial Performance - The company's operating revenue for the first half of 2022 was ¥344,578,465.20, a decrease of 14.13% compared to ¥401,275,143.40 in the same period last year[18]. - The net profit attributable to shareholders for the first half of 2022 was ¥27,146,609.00, down 72.55% from ¥98,899,969.23 in the previous year[18]. - The net cash flow from operating activities was -¥42,404,998.19, representing a decline of 36.35% compared to -¥31,100,027.12 in the same period last year[18]. - Basic earnings per share decreased by 72.41% to ¥0.16 from ¥0.58 in the previous year[18]. - The total assets at the end of the reporting period were ¥968,673,474.97, a slight decrease of 0.17% from ¥970,345,939.68 at the end of the previous year[18]. - The net assets attributable to shareholders decreased by 1.70% to ¥744,957,382.90 from ¥757,810,648.61 at the end of the previous year[18]. - The company reported a significant decline in net profit excluding non-recurring gains and losses, which was ¥20,190,495.82, down 79.31% from ¥97,580,250.47 in the previous year[18]. - The weighted average return on net assets decreased to 3.55% from 14.13% in the previous year, a drop of 10.58%[18]. Dividend and Fund Management - The company plans not to distribute cash dividends or issue bonus shares[4]. - The company reported a total of 21,690 million RMB in fundraising, with 1,228.7 million RMB used in the current period and a cumulative total of 23,286 million RMB used[48]. - The actual net fundraising amount was 216,905,303.28 RMB after deducting related expenses from a total of 255,721,600.00 RMB raised[49]. - The company has permanently supplemented its working capital with remaining fundraising amounts, including 93,175,084.67 RMB from the marketing network construction project[51]. - The company has not reported any unutilized raised funds or issues with the disclosure of fund usage, ensuring compliance with regulations[56]. - The company plans to incorporate the costs of terminated projects into its normal budget expenditures, reflecting a strategic shift in resource allocation[55]. Project Termination and Strategic Adjustments - The company terminated the "Marketing Network Construction Project" and will permanently supplement the remaining raised funds into working capital, citing changes in the domestic daily chemical market and increased competition as reasons[54]. - The "Daily Chemical Production Line Technology Renovation Project" was also terminated, with the company stating that the existing production capacity is sufficient to meet near-term product demand[54]. - The total investment amount for the terminated projects was 21,690 million, with 1,228.7 million already invested[54]. - The decision to terminate projects was made after careful consideration of market conditions and the company's product lifecycle[54]. - The company aims to adapt to emerging marketing channels and consumer trends while managing investment risks effectively[54]. Market Presence and Brand Development - The company has been engaged in the daily chemical industry since its establishment in 1994, focusing on health care products such as shampoos, conditioners, and skincare products[26]. - The company entered the gaming industry through an acquisition in August 2020, primarily focusing on game development and commercialization, with plans to expand into self-publishing and external agency operations[26]. - The company has developed a strong brand presence with notable brands like "Tihua Zhi Xiu" and "Mei Wang," which have been recognized as "Famous Trademarks of Guangdong Province"[29]. - The company has approximately 40,000 retail outlets across the country, with a significant presence in third and fourth-tier cities, and is actively expanding into first and second-tier markets[31]. - The company aims to enhance its market position by leveraging its technical development capabilities and rich market operation experience in the gaming sector[28]. Research and Development - The company has established a comprehensive R&D system with 1,008 independent intellectual property trademarks, 49 technology patents, and 88 design patents, positioning itself as a leader in local daily chemical R&D[32]. - Research and development expenses rose by 8.48% to ¥49,782,843.77, reflecting the company's commitment to enhancing its product offerings[36]. - The company has a strong and stable R&D team, with core members having over 8 years of industry experience, which is crucial for game quality[33]. Operational Efficiency and Challenges - The company has established a stable and efficient operational process, successfully validating projects with monthly revenues exceeding ¥100 million[33]. - The company is committed to technological innovation, with a focus on providing safe, healthy, and high-quality consumer experiences through its product offerings[26]. - The company is facing increased competition in the daily chemical market, with a notable rise in market penetration rates for various brands[55]. - The management highlighted the impact of the COVID-19 pandemic on market conditions and consumer behavior, leading to a reassessment of investment strategies[54]. Shareholder and Governance Matters - The company has implemented measures to enhance investor rights protection, ensuring timely and accurate information disclosure and facilitating shareholder participation in meetings[78]. - The company has not experienced any financial misconduct involving major shareholders or related parties, maintaining a clean financial record[79]. - The company has established a governance structure including a shareholders' meeting, board of directors, and supervisory board[172]. Future Outlook - The company plans to focus on enhancing operational efficiency and shareholder value in light of the current market environment[54]. - The company aims to optimize traditional distribution channels and enhance retail network construction, targeting stable growth in revenue and net profit for the second half of 2022[63]. - The company plans to expand its market presence and invest in new product development to drive future growth[164].

名臣健康用品股份有限公司 2021 年年度报告全文 名臣健康用品股份有限公司 2021 年年度报告 2022 年 04 月 1 名臣健康用品股份有限公司 2021 年年度报告全文 第一节 重要提示、目录和释义 公司董事会、监事会及董事、监事、高级管理人员保证年度报告内容的真 实、准确、完整，不存在虚假记载、误导性陈述或重大遗漏，并承担个别和连 带的法律责任。 公司负责人陈建名、主管会计工作负责人彭小青及会计机构负责人(会计主 管人员)林耀麟声明：保证本年度报告中财务报告的真实、准确、完整。 所有董事均已出席了审议本报告的董事会会议。 本报告中涉及未来发展规划等事项的前瞻性陈述，不构成公司对投资者的 实质承诺，投资者及相关人士均应对此保持足够的风险认识，并且应当理解计 划、预测与承诺之间的差异，请投资者注意投资风险。 公司在本报告"第三节 管理层讨论与分析"中"十一、公司未来发展的展望" 部分描述了公司未来经营中可能面对的风险，敬请广大投资者注意查阅。 公司经本次董事会审议通过的利润分配预案为：以 122135745 为基数，向 全体股东每 10 股派发现金红利 3.00 元（含税），送红股 0 股（含税），以 ...

Financial Performance - The company's revenue for Q1 2022 was ¥149,012,185.35, a decrease of 31.24% compared to ¥216,717,972.68 in the same period last year[3] - Net profit attributable to shareholders was ¥1,638,200.89, down 97.39% from ¥62,676,044.09 year-on-year[3] - The total operating profit for the first quarter was CNY 1,050,322.55, compared to CNY 63,385,335.93 in the previous year, indicating a decrease of about 98.3%[20] - The net profit for the first quarter of 2022 was CNY 1,638,200.89, a significant decrease from CNY 62,676,044.09 in the same period last year, reflecting a decline of approximately 97.4%[20] - The company's total comprehensive income for the first quarter was CNY 1,638,200.89, down from CNY 62,676,044.09 in the same period last year[21] - The company's basic and diluted earnings per share for the first quarter were both CNY 0.01, a decrease from CNY 0.51 in the previous year[21] Cash Flow - The net cash flow from operating activities was -¥70,501,835.42, representing a decline of 112.56% compared to -¥33,167,525.98 in the previous year[3] - The cash flow from operating activities showed a net outflow of CNY 70,501,835.42, worsening from a net outflow of CNY 33,167,525.98 in the previous year[24] - The total cash inflow from operating activities was CNY 165,458,573.09, down from CNY 196,712,464.26 year-over-year[24] - The cash flow from investing activities resulted in a net outflow of CNY 65,252,988.05, compared to a net outflow of CNY 17,304,670.41 in the previous year[24] - The cash and cash equivalents at the end of the period were CNY 114,077,895.54, down from CNY 147,257,380.50 at the end of the previous year[25] - Cash and cash equivalents at the end of Q1 2022 were RMB 114,077,895.54, down from RMB 250,898,429.01 at the beginning of the year[15] Assets and Liabilities - The company's total assets decreased by 2.38% to ¥947,253,566.02 from ¥970,345,939.68 at the end of the previous year[3] - Total assets as of March 31, 2022, were RMB 947,253,566.02, a decrease from RMB 970,345,939.68 at the beginning of the year[17] - Total liabilities decreased to RMB 187,804,716.52 from RMB 212,535,291.07 at the beginning of the year[17] Operating Costs and Margins - Total operating costs for Q1 2022 were RMB 142,910,650.51, down from RMB 152,956,064.09 in the previous period[19] - Gross profit margin for Q1 2022 was approximately 4.7%, compared to a higher margin in the previous period[19] Shareholder Information - The company has a total of 6,369 common shareholders as of the end of the reporting period[10] Investments and Acquisitions - The company plans to acquire 100% equity of Kashgar Aochu Network Technology Co., Ltd. for RMB 21,900,000, with a 30% deposit already paid[12] Financial Assets and Income - The company reported a significant increase in financial assets, with trading financial assets rising by 478.77% to ¥69,196,991.55[6] - Other income increased by 143.28% to ¥303,606.33, primarily due to an increase in government subsidies[7] - The company reported interest income of CNY 527,475.59, an increase from CNY 467,844.02 in the previous year[20] - The company incurred financial expenses of CNY -264,467.98, compared to CNY -74,761.37 in the same period last year[20] Research and Development - Research and development expenses for Q1 2022 were RMB 24,383,528.86, compared to RMB 22,359,923.96 in the previous period[19] Inventory and Accounts Receivable - Inventory at the end of Q1 2022 was RMB 134,643,845.68, slightly up from RMB 133,010,293.74 at the beginning of the year[15] - Accounts receivable increased to RMB 227,542,457.17 from RMB 209,736,137.63 at the beginning of the year[15] Credit Impairment - The company experienced a 345.61% increase in credit impairment losses, totaling -¥5,805,743.17, due to higher provisions for bad debts[7]